A New Hope for Pancreatic Cancer: PARP Inhibitors in Tumors With BRCA Mutations

Expert discussion of key data on the use of PARP inhibitors in patients with pancreatic cancer and BRCA mutations.

Disclaimer:
Not an official event of the 2019 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.

Agenda

7:00 PM  Program Overview

7:05 PM  Overview of Germline Mutations in Pancreatic Cancer

7:20 PM  DNA Damage Repair Defects as a Therapeutic Target in Pancreatic Cancer: The Role of PARP Inhibitors

7:50 PM  Ongoing Clinical Trials and Combination Strategies in PDAC With Germline or Somatic DDR Mutations

8:20 PM  Closing Remarks and Audience Question and Answer Session

Events

Date / Time
Event Details
1/18/2019
6:30 PM

Faculty

Program Director
John Marshall, MD

Chief, Division of Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Faculty
Tanios Bekaii-Saab, MD, FACP

Professor 
Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic Arizona
Phoenix, Arizona

Faculty
Eileen O'Reilly, MD

Winthrop Rockefeller Chair in Medical Oncology
Section Head, 
Hepatopancreaticobiliary/Neuroendocriine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Medical College
New York, New York

CME

Goal Statement
The goal of this activity is to improve participants’ knowledge of, confidence in, and competence in integrating PARP inhibitors into treatment of patients with pancreatic cancer.

Target Audience 
This program is intended for physicians and other healthcare providers who care for patients with pancreatic cancer.

Learning Objectives

  • Describe the rationale for assessing BRCA1/2 and other DNA damage repair gene alterations in pancreatic cancer
  • Examine the mechanism of PARP inhibition to achieve "synthetic lethality" in pancreatic ductal adenocarcinoma with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat pancreatic ductal adenocarcinoma harboring BRCA1/2 or other DNA damage responsemutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitors as monotherapy or in combination with other agents in pancreatic ductal adenocarcinoma

Accreditation

Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Education
CCO designates this live activity or enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.